SpringerLink
Log in

Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

About 50 % of patients with diffuse large cell lymphoma are candidate for salvage chemotherapy followed by bone marrow transplantation in the selected patients. In the current study we evaluated modified ICD (Irinotecan, Cisplatin, and Dexamethasone with G-CSF support) as salvage chemotherapy in the patients previously treated with R-CHOP or CHOP. In a retrospective study we evaluated 16 patients treated with modified ICD: irinotecan 65 mg/m2 (max 100 mg)/day plus cisplatin 30 mg/m2 (max 50 mg)/day and dexamethasone 40 mg/day on days 1 and 8. Prednisolone 200 mg divided in 2 doses was given orally on days 2 and 9. G-CSF (PDgrastim) was administered at 300 μg/day subcutaneously on days 4–6 and 11–13. pre- and post-hydration was given according to our hospital protocol. Overall response rate was 75 % for all of the patients and 90 % for the patients treated as first line salvage. The median overall survival was 23 ± 12 months. There was no grade 3/4 of neutropenia and no cycles of chemotherapy were delayed due to leucopenia. Modified ICD might be an effective salvage regimen for refractory/relapsed lymphoma patients. Unlike original ICD, leucopenia does not seem to be a limiting factor. So we conclude that modified ICD shall be considered as a safe and effective regimen for salvage chemotherapy in refractory/relapsed patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hill M, Kyle F (2008) NHL (diffuse large B cell lymphoma). Clin Evidence (Online) 2008:2401

    Google Scholar 

  2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190. Epub 2010 Jul 26

    Article  PubMed Central  PubMed  Google Scholar 

  3. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N (2008) Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Investig 26(4):401–406

    Article  CAS  Google Scholar 

  4. Kang HJ, Kim WS, Suh C, Park YH, Kim BS, Yuh YJ, Ryoo BY (2008) Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer Chemother Pharmacol 62(2):299–304

    Article  CAS  PubMed  Google Scholar 

  5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas. J Clin Oncol 17(4):1244–1253

    CAS  PubMed  Google Scholar 

  6. Niitsu N, Kohori M, Higashihara M, Bessho M (2007) Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 98(1):109–112

    Article  CAS  PubMed  Google Scholar 

  7. Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B (2008) Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. J Chemother 20(5):640–644

    Article  CAS  PubMed  Google Scholar 

  8. Kanat O, Ozet A, Ataergin S, Arpaci F, Kuzhan O, Komurcu S, Ozturk B, Ozturk M (2010) Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. Med Princ Pract 19(5):344–347

    Article  PubMed  Google Scholar 

  9. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB (2008) North Central Cancer Treatment Group Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 49(6):1074–1080

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran

    Mojtaba Ghadiany, Hamid Rezvani & Abbas Haji Fathali

  2. Department of Hematology and Oncology, Yazed University of Medical Science, Yazd, Iran

    Mohammad Foratyazdi

  3. Department of Hematology and Oncology, Mashhad University of Medical Science, Mashhad, Iran

    Hossein Rahimi

  4. Tehran, Iran

    Lila Sadeghi

Authors
  1. Mojtaba Ghadiany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Foratyazdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hamid Rezvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lila Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abbas Haji Fathali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mojtaba Ghadiany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghadiany, M., Foratyazdi, M., Rahimi, H. et al. Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma. Indian J Hematol Blood Transfus 30, 265–268 (2014). https://doi.org/10.1007/s12288-013-0269-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-013-0269-9

Keywords

Search

Navigation